Tilray Inc (NASDAQ:TLRY – Get Free Report)’s stock price shot up 1.2% during trading on Tuesday . The company traded as high as $1.74 and last traded at $1.71. 7,442,829 shares changed hands during mid-day trading, a decline of 70% from the average session volume of 24,966,674 shares. The stock had previously closed at $1.69.
Tilray Stock Performance
The company has a market cap of $1.34 billion, a PE ratio of -3.89 and a beta of 2.13. The business’s 50-day moving average is $1.81 and its 200 day moving average is $1.88. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.42 and a current ratio of 2.27.
Tilray (NASDAQ:TLRY – Get Free Report) last announced its quarterly earnings results on Monday, July 29th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The firm had revenue of $229.90 million during the quarter, compared to the consensus estimate of $226.20 million. Tilray had a negative return on equity of 2.63% and a negative net margin of 30.26%. Tilray’s revenue was up 24.8% on a year-over-year basis. During the same period last year, the business earned ($0.15) EPS. On average, equities research analysts predict that Tilray Inc will post -0.16 EPS for the current fiscal year.
Institutional Investors Weigh In On Tilray
Tilray Company Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Further Reading
- Five stocks we like better than Tilray
- The Most Important Warren Buffett Stock for Investors: His Own
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- EV Stocks and How to Profit from Them
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Investing In Preferred Stock vs. Common Stock
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.